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Abstract
Background: In specific situations it may be necessary to make an exception to the general rule of informed
consent for scientific research with an intervention. Earlier reviews only described subsets of arguments for
exceptions to waive consent.
Methods: Here, we provide a more extensive literature review of possible exceptions to the rule of informed
consent and the accompanying arguments based on literature from 1997 onwards, using both Pubmed and
PsycINFO in our search strategy.
Results: We identified three main categories of arguments for the acceptability of a consent waiver: data validity
and quality, major practical problems, and distress or confusion of participants. Approval by a medical ethical
review board always needs to be obtained. Further, we provide examples of specific conditions under which
consent waiving might be allowed, such as additional privacy protection measures.
Conclusions: The reasons legitimized by the authors of the papers in this overview can be used by researchers
to form their own opinion about requesting an exception to the rule of informed consent for their own study.
Importantly, rules and guidelines applicable in their country, institute and research field should be followed.
Moreover, researchers should also take the conditions under which they feel an exception is legitimized under
consideration. After discussions with relevant stakeholders, a formal request should be sent to an IRB.
Keywords: Informed consent, Consent waiver, Research ethics
Background
Despite the widespread agreement on the legal and ethical
appropriateness of the general rule of informed consent
for human research with an intervention, there are exam-
ples of very specific situations in which there are reasons
to make an exception. An example is health research that
can only be conducted on incapacitated patients, such as
resuscitation research [1].
Over the years, informed consent requirements have
undergone some notable changes. The Nuremberg Code
was written in response to Nazi war crimes, and stated
that informed consent for research is ‘absolutely essential’.
An important change in this statement was introduced
with the Declaration of Helsinki in 1964, which also
allowed proxy consent from a relative in case the subject
was unable to make this decision. Policy surrounding
waiving consent remains a topic of debate within the
scientific literature. Following publication in 1997 of
two papers were published, describing studies in which
no informed consent was asked [2, 3], the Editor of BMJ
invited readers to share their viewpoint on whether
publishing these articles was the right decision [4]. This
invitation led to the largest volume of correspondence
on any specific topic in the history of BMJ. The many
recent papers on this topic (e.g. [5–7]) in various scientific
journals, indicate that this debate is still ongoing.
In the context of an earlier intervention study that we
conducted comparing three different consent procedures
for the use of residual tissue for scientific research [8],
we perused the literature for examples of other studies
in which consent was waived, and the conditions under
which such a waiver was applied. Most of the literature
that we found was focused on only one subset of reasons,
or reasons given for only one specific type of research in
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which the informed consent requirement can be waived.
For example, Biros et al [5] provided an overview of
conditions under which the American Food and Drug
Administration (FDA) permits research in medical
emergency circumstances without consent. Giraudeau et
al [9], in a review of cluster randomized trials, found that
less than 5 % of such trials explicitly stated that no individ-
ual level informed consent was required. Other papers
have focused on reasons not to ask informed consent in
the control group of a randomized controlled trial,
commonly known as Zelen’s design or a prerandomization
design [10].
To the best of our knowledge, no paper has yet provided
a more comprehensive review of the range of arguments
and circumstances under which the informed consent re-
quirement in intervention research might be waived. We
believe that such a review can serve as an important source
document for researchers, institutional review boards, and
policy makers involved in establishing the legal and ethical
standards of research with human subjects. The discussion
about when informed consent is necessary is not recent
(e.g. [11]). However, societal developments lead to new
insights, and changes in research interests lead to new
discussions. Therefore, our aim is to provide a review
of contemporary reasons to waive informed consent. For
that reason, we reviewed the literature starting from the
discussion in BMJ. In the discussion, we also reflect on the
arguments brought forward in the reviewed papers.
Methods
We reviewed the literature cited in Pubmed and PsycINFO,
from April 1997, the year in which the discussion of excep-
tions to informed consent was started in BMJ, to September
2013. We searched Pubmed.gov using the following search
terms: ((("informed consent"[MeSH Terms] AND "epidemi-
ologic studies"[MeSH Terms] AND "data collection"[MeSH
Terms]) AND (Review[ptyp] OR Randomized Controlled
Trial[ptyp] OR Letter[ptyp] OR Clinical Trial[ptyp] OR
Journal Article[ptyp])) OR (("clinical trials as topic"[MeSH
Terms] AND "informed consent"[MeSH Terms] AND
"ethics, research"[MeSH Terms]) AND (Review[ptyp]
OR Randomized Controlled Trial[ptyp] OR Clinical
Trial[ptyp] OR Journal Article[ptyp])) OR ("informed
consent"[MeSH Terms] AND "intervention studies"[MeSH
Terms]) OR ("informed consent"[MeSH Terms] AND "epi-
demiology"[MeSH Terms]) OR (Consent[All Fields] AND
waiver[All Fields])) AND (("1997/04/12"[PDAT] : "2013/08/
31"[PDAT]) AND English[Language]).
We searched the PsycINFO database using the following
search terms: ((DE "Informed Consent" AND DE "Data
Collection" AND DE "Epidemiology") OR (DE "Informed
Consent" AND DE "Clinical Trials" AND DE "Ethics") OR
(DE "Informed Consent" AND DE "Intervention") OR
(DE "Informed Consent" AND DE "epidemiology") OR
(Consent waiver)) AND LA English AND ED 19970412-
20130831 AND PT Peer Reviewed Journal.
Doyal and Tobias collected and published in book form
all correspondence in BMJ regarding the two papers where
a waiver of informed consent [12]. We included all letters
in this book in this review. When reasons in these letters
were cited by other discussants, we only cited the original
author.
Eligible articles discussed reasons not to ask informed
consent and/or conditions under which an exception to
the rule of informed consent was deemed acceptable.
We only included reasons and conditions if they applied
to informed consent for scientific research with an inter-
vention, including research with a Zelen (prerandomiza-
tion) design and deferred consent. We excluded research
on children and articles addressing reasons to use proxy
consent (surrogate consent) from family members or part-
ners instead of patients themselves (e.g. [13]). Importantly,
our search strategy was not aimed at identifying papers
about the content of the informed consent procedure, such
as the completeness or accuracy of information given to
participants before the start of an intervention study. For
example, there has been much discussion about the use of
deception in informed consent about the research goal of a
study in psychology (e.g. [14]). Although the content of in-
formed consent forms is important and related to the topic
of this review, it is beyond the scope of this paper.
The process and decisions on the inclusion and exclu-
sion criteria were discussed with all authors. Then, one
of the authors (SR) made a selection of articles based on
the title and abstract, and evaluated the selected articles
for the inclusion and exclusion criteria (Fig. 1).
Results
In total 1348 records were identified (Fig. 1). After de-
tailed assessment of eligibility, 115 papers were included
in the review. We would note that all arguments given,
and the judgements given about these arguments, in the
results section do not necessarily reflect the opinions of
the authors of this paper, but refer to the opinions and
judgements of the authors of the 115 papers included in
this review.
Major reasons for exclusion were papers describing
research without an intervention (e.g., observational
studies), pediatric intervention studies, or papers focusing
on reasons to obtain proxy consent. Papers identified
through pubmed.gov were not taken into account in the
PsycINFO search. From the 115 papers included, we iden-
tified three main categories of reasons for waiving the in-
formed consent requirement: (1) decrease of data validity
and quality; (2) distress or confusion of participants; and
(3) practical problems. Ethical issues play a role in each of
the three categories, as an overarching theme. Therefore,
we also included a fourth category focusing on ethical
Rebers et al. BMC Medical Ethics  (2016) 17:9 Page 2 of 11
reasons or objections to waiving informed consent. We
present here all arguments and conditions mentioned in
these four categories (the order of the categories and argu-
ments were randomly chosen). For any given argument,
all papers mentioning this argument are cited.
Decrease of data validity and quality
Concerns about the effect of asking informed consent
on the quality or validity of outcome data are prevalent
in the literature. These concerns are specifically relevant
when study outcomes are self-reported, when bias is
likely to occur, or when the inclusion rate is highly
compromised because of asking informed consent. Many
of the examples in this section come from proponents of
the Zelen design, in which no consent is asked for
randomization [15]. After randomization, researchers ask
subjects allocated to the intervention group for informed
consent, while subjects in the control group remain in the
study without being informed of the randomization
procedure.
It has been argued that asking informed consent in
studies in which outcomes are self-reported may result in
poor data quality, most notably through the ‘Hawthorne ef-
fect’ or through ‘resentful demoralization’. The “Hawthorne
effect” argument has most typically been raised by investi-
gators working in implementation science where subjects’
behavior and thus the outcome of a study is likely to be in-
fluenced significantly by the subjects’ awareness of being
part of that study [16–19]. Examples include studies of pa-
tient compliance [20], cluster randomized trials in which
the effect of offering physicians an intervention to improve
uptake of clinical guidelines is studied [21], and studies on
the effect of offering a screening tool for the detection of
violence at home [22]. In some cases, the consent process
is also thought to bias the study outcome [23], for instance
when the study is aimed at comparing patients who re-
ceived information on a topic with patients who were not
informed. An informed consent procedure gives patients in
the control group information about the topic, which
makes them more similar to patients in the intervention
group than desirable.” Resentful demoralization” is a term
used to describe the impact of the disappointment of being
randomized to the control group on self-reported outcomes
or outcome behavior [24–27]. Some authors also expect a
bias if a preference for the intervention arm influences the
validity of a study due to differential drop-out [28]. An ex-
ample is a study in which researchers provided the drug
heroin to addicted persons; many participants withdrew
from the study after being randomized to the control group
[24, 29]. Institutional Review Board (IRB) approval is often
mentioned as a necessity when waiving consent in these
cases [16, 18].
Some authors argue that selection bias or participation
bias may also decrease the validity of study results [10, 30].
Physicians might, for example, be less likely to ask cer-
tain patient groups (e.g., those with a perceived lower
Fig. 1 Selection process of eligible studies on reasons to waive informed consent. Search terms are described in the methods section of this paper
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intelligence or with social or emotional problems) to
consent for research [24]. They further argue, that some
patient groups might be less likely to give consent than
others [3, 31], such as minority group members [32, 33] or
unskilled workers, while other patient groups, especially in
emergency research, may not be able to consent at all [34].
In such situations, the outcome of such a study may ad-
dress the efficacy of treatment among those who consent,
while the investigators may be more interested in evaluat-
ing the effectiveness of the intervention in a real world set-
ting (i.e., implementation research) [10, 33]. It has been
suggested that for a waiver to be acceptable in these cases,
all identifiable data should be discarded at the end of the
study [35].
Some also expect bias might be introduced when in-
formed consent is asked from all health care workers in
a cluster randomized trial [7]. In this case, it has been
suggested that an IRB may grant a waiver, provided the
researchers provide compelling evidence that the results
would be non-interpretable without the waiver, and that
a different study design could not overcome this problem.
Further, a cluster representative, i.e., a representative of
the patient group concerned, should agree to the enroll-
ment of the cluster in the study [21].
A higher inclusion rate has also been mentioned as a
reason not to ask for informed consent [10, 24, 36, 37],
especially in intensive care trials [37], where inclusion of
a relatively small number of patients might otherwise
take years. A low inclusion rate could further lead to
poor data validity and quality, because it might result in
physicians being less accurate in following the study
protocol [38]. Moreover, especially in emergency research,
where it may be unacceptable to delay start of treatment
due to consent procedures, such a delay may also lead to
an underestimation of the treatment effect [39, 40].
Distress or confusion of participants
The second major argument often mentioned in the lit-
erature for making an exception to the rule of informed
consent in specific situations is that a consent procedure
might lead to unnecessary distress or confusion on the
participants’ part [16]. The informed consent procedure
itself may generate such distress or confusion. For example,
severely ill patients who are focused on their treatment and
recovery [41], and who may already be quite anxious [42],
may find it disturbing to be informed about a study.
Similarly, the stressfulness of the medical situation is
thought to inhibit potential study participants from
grasping the rationale of the study, especially in emergency
research [36, 37, 43], for example when patients have
suffered an acute myocardial infarction [36]. Others
have argued that patients might also be negatively af-
fected by the knowledge that their physician does not
know which treatment is best [44, 45].
Being randomized to the control group after being
given information about the intervention arm of a study
might be especially confusing or disappointing for pa-
tients [24, 36, 46]. Some argue that the Zelen design is a
more humane way to deal with patients’ expectations of
receiving a novel treatment [10], and it may reduce dis-
tress associated with knowing that the physician does
not always know which treatment is best [45]. Moreover,
Homer [24] has argued that use of the Zelen design may
also avoid damaging the doctor-patient relationship.
Practical problems
The impossibility of informed consent in emergency research
Emergency research is the most often mentioned example
in all contexts described, and it is the most notable research
discipline in which practical problems are forwarded as the
primary reason why the informed consent requirement
should be waived. This is because it is simply impossible to
ask (temporarily) incapacitated patients for informed con-
sent [1, 5, 23, 33, 34, 36, 38, 40, 43, 45, 47–95]. Patient pop-
ulations often mentioned in this context are those with
acute head or brain injuries [5, 25, 34, 38, 39, 74, 96], and
comatose, unconscious or sedated patients [49, 92], al-
though a much wider range of relevant patient populations
has also been named [40, 58, 60, 63, 65, 66, 97–105].
Specifically in the context of emergency research, an
often-mentioned reason to waive informed consent is that
the main alternative, proxy consent, is often not possible
either [87, 99]. This is especially the case when the treat-
ment window is short [1, 5, 23, 25, 32, 34, 36, 37, 43, 56,
57, 61, 63, 65, 68, 69, 77, 80, 96, 98–100, 103, 104, 106].
Others have mentioned that asking proxy consent could
be inappropriate, for instance when testing HIV status
[90]. Prospective consent [104], e.g., asking informed con-
sent for a study on the treatment of cardiac arrest before
the cardiac arrest occurs, is often impossible, because it is
not possible to identify these patients prospectively. It has
also been argued that deferred consent (i.e., informed con-
sent that is postponed to a later point in time [39, 68, 75,
87, 91, 99]), may not be a legitimate alternative because
many patients do not survive their illness [90].
There has been much discussion in the literature about
the conditions that should be met when conducting emer-
gency research with a waiver of consent. First, the condi-
tion preventing patients from giving informed consent
should be a characteristic of the population being studied
[63, 68, 75, 91], and the study should be aimed at improv-
ing the care of that population [43]. Patients’ previously
expressed objections should be respected [75, 87], and
both the patient and the data should be appropriately
protected [5, 33, 43, 90]. In the absence of consent, it is
thought to be particularly important to consider conducting
minimal risk research if possible, and to always carefully
weigh the risks in relation to the potential benefit to
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the patient [43, 68, 87, 91]. There should be unanimous
agreement among relevant individuals about the import-
ance of the research and the impracticability of informed
consent [90]. Further, an independent board should
evaluate serious adverse events [99], and IRB approval
is necessary [43, 47, 48, 52, 72, 75, 79, 99]. In order to
avoid a financial conflict of interest, researchers should
not be paid to include patients in the study [99]. An inde-
pendent physician or advisory board could also consent
on the patient’s behalf in such situations [39, 58, 68, 75,
99]. It has further been argued that, for waiver of informed
consent to be acceptable, no alternative procedures of
equal effectiveness should be available, there should be no
intention to give participants feedback of information, and
no decisions should be made that affect them [71].
Regulations for emergency research with a waiver
Many of the reviewed articles refer to conditions in offi-
cial regulations [1, 5, 6, 23, 32, 34, 36, 37, 39, 45, 49, 52,
53, 55–57, 60, 61, 64, 65, 68–70, 73, 74, 76, 77, 80–83,
85, 86, 88, 95, 101, 103, 107–112], such as the ‘Final
Rule’ of the U.S. Food and Drug Administration (FDA).
The FDA amended its informed consent regulations in
1996 in order to ensure that emergency research could
be carried out without informed consent in certain situa-
tions. The U. S. Department of Health and Human Services
(DHHS) adopted these rules, known as the ‘final rule for
waiver of informed consent in certain emergency research
circumstances’.
According to this ‘final rule’, researchers should consult
representatives of the community from which the subjects
will be drawn before the start of the study. This provides
the opportunity to express one’s views on the proposed
study. The IRB must then take these views into account
when reviewing the request for the consent waiver. After
IRB approval, researchers should publicly disclose the risks
and benefits of the study before it starts and after its com-
pletion. These risks and benefits should be reasonable in
relation to the patient’s condition. It should be made clear
that incapacitated individuals may be enrolled without
consent from a proxy. The researcher should, however,
attempt to contact the patient’s legally authorized rep-
resentative within the therapeutic window to determine
whether they object to participation. If this is not possible,
the proxy or patient should be informed as soon as pos-
sible, and if the study is still ongoing at that moment, con-
sent should be asked to continue participation. Further, the
study’s sponsor should establish an independent data moni-
toring committee. This committee must exercise oversight
of the study, and may recommend continuing, modifying,
or stopping the study, dependent on its progress. Moreover,
there should be evidence from prior research that the
intervention has the potential to benefit patients, while
the available treatments are unproven or unsatisfactory.
Patients themselves should be in a life-threatening situ-
ation that necessitates intervention. It should further be
clear that the study couldn’t reasonably be conducted
otherwise. For instance, there should be no way in which
subjects can be identified prospectively.
In the U.S., government-funded research is further
held against an ethical standard known as the ‘common
rule’. When it is not practical to obtain consent, the
common rule states that an IRB may permit a waiver of
consent when the study evaluates public benefit or service
programs, procedures for obtaining benefits or services
under those programs, possible changes in or alternatives
to those programs or procedures, or possible changes in
methods or levels of payments for benefits or services
under those programs. The Council of Europe has also
developed a set of rules on bioethics, which sometimes
allows research without consent in those who do not
have the capacity to consent [4].
The Declaration of Helsinki also gives exceptions for
the rule of informed consent under certain circumstances
[4, 39, 45, 54, 99, 113]. A waiver of consent may be
granted when subjects are physically or mentally unable
to give consent, and when the condition that causes
this inability is a necessary characteristic of the research
population. Further, attempts to obtain proxy consent
should have failed within the therapeutic window. IRB
approval should be obtained, and consent to remain in
the study should be obtained as soon as possible from
the subject or proxy.
Other practical problems
There are also other practical problems that authors
have suggested may play a role in the argumentation to
waive informed consent. A waiver could increase the
recruitment rate [5, 10, 38, 114], and decrease the ad-
ministrative task [16, 45] and resources spent on the
study [10]. Further, it may increase the speed at which
the study treatment is initiated [37, 38, 68, 76, 87]. Not
asking informed consent in these situations may be done
under the condition that monitoring of adverse effects
takes place, and that this may lead to an intervention
[114]. The Zelen design is considered to be an alternative.
Another logistical difficulty that has been brought up is
time. In case of a public health emergency, such as epi-
demics of dangerous contagious diseases, there may not
be enough time to ask informed consent [25].
Examples of logistical difficulties are cluster random-
ized trials with large groups of participants [7, 21, 115],
or a study on large groups of military personnel going to
the Middle-East [62]. This latter example has been ex-
plicated by Cummings [62]. The U.S. military wanted
to vaccinate 2.4 million troops against inhalation anthrax
while it was still an investigational drug, and argued
that it was impossible to ask informed consent for this
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mandatory vaccination. The conditions under which a
waiver might be allowed that were mentioned in this
paper were the provision of information sheets, careful
documentation of whom is given the vaccination and of
adverse reactions, and approval of the IRB, FDA com-
missioner, and the President of the U.S. Further, there
should be a public notice of the study.
In cluster randomized trials, the intervention and
randomization are on another level than the outcome,
for example, in a trial in which a group of physicians
receives training and another group does not, and the
outcome is a measure of the patients’ health. An example
would be a study in which physicians in the intervention
arm would, among other measures, be educated about
procedures to prevent catheter-related infections, while
the outcome, the number of catheter-related infections, is
on the level of the patient. It has been argued that in-
formed consent is useless if it is impossible for both
patients [21] and healthcare workers to avoid interven-
tions conducted at the level of a complete department or
hospital [7].
Ethical reasons or objections
Ethical reasons that are proposed to legitimize a consent
waiver often relate to, or are consequences of the argu-
ments given in the above paragraphs. Therefore, they
can also be divided into the same three categories (de-
crease of data validity and quality; distress or confusion;
and practical problems). It might be unethical to con-
duct research knowing that the validity of the study re-
sults will be compromised. When it is known the results
are probably not valid [20, 116], for instance when they
are biased [21, 26, 31], it is unethical to spend resources
and the participants’ time on research. Further, it might
be unethical to distress patients by discussing an experi-
mental treatment with them, after which they are allocated
to the control group of the study.
The practical problems with informed consent, espe-
cially those in emergency research [1, 34, 39, 49, 63, 84,
85, 99, 108, 117], are thought to lead to ethical problems
as well. For instance, it is considered to be unethical to
delay treatment initiation because of an informed con-
sent procedure when it is expected that this delay will
adversely affect treatment outcome.
However, not all ethical arguments relate directly to
arguments in the other categories. In these cases, au-
thors often conduct an ethical analysis, in which they
systematically explore the consequences of the different
choice options on several fundamental values, such as
autonomy, justice, beneficence, or non-maleficence. Com-
monly, in intervention research, autonomy forms the basis
of informed consent. It is argued, however, that respect for
autonomy is not valid or is less valid for emergency
patients, such as those with traumatic brain injury [34].
Other principles that are relevant for these cases are the
prospect of therapeutic benefit, and the protection against
potential harm of the intervention. These authors stress
the importance of conducting a risk-benefit analysis. A
waiver of consent should only be allowed if the risks are
acceptable, considering the gravity of the disease [34] and/
or the potential therapeutic benefit [43]. Further, it should
be ensured that this vulnerable patient group is protected
from exploitation due to their incapacitated status [34,
43]. Kompanje further argues that an independent safety
committee should be instituted to assess these cases [34].
Risk-benefit analyses sometimes also include benefits
on the broader societal level. Some then argue that not
asking informed consent may be the most ethically
correct thing to do, because it is beneficial for future
patients or for society as a whole [3, 35, 39, 41, 54, 57,
63, 76, 84, 85, 108, 118–121]. Informed consent might,
for example, prevent or delay progress being made in
critical clinical situations which, in turn, could lead to
increased mortality or disability, such as in traumatic
brain injury [34, 40, 41, 55, 57, 61, 68, 71, 108]. Moreover,
if it was not possible to conduct research on emergency
care patients without informed consent, patients could be
exposed to potentially hazardous effects of invalid and in-
effective clinical practice [63]. Evans also noted that it
could be argued that patients should participate in scien-
tific research in countries with publicly funded health care,
provided the studied treatments are equal in expected
treatment outcome [114].
A last group of ethical arguments relates to the idea
that it can be ethically unnecessary and/or unreasonable
to ask informed consent in specific types of research.
Specific conditions, such as the removal of identifiable
data [7], the possibility to have data removed on request,
or providing information after the end of the study [20]
may apply. Main examples are low-risk research types,
such as cluster randomized trials [7, 16, 21, 37, 115,
116]. A final argument in this last category is that it is
not necessary to obtain consent in the control group
and/or the intervention group when the treatments in
these arms are routinely used [46, 60].
Figure 2 visualizes the relationships between different
study types and different reasons for not requiring in-
formed consent.
Discussion
We summarized the different arguments given in the
literature to make an exception to the general rule of
informed consent. We deliberately did not weigh the
number of times arguments were mentioned, because
we felt frequency was not related to legitimacy of the
argument. However, here we will put the arguments in
a broader perspective, in which the frequency of arguments
may sometimes be relevant. Three themes emerged from
Rebers et al. BMC Medical Ethics  (2016) 17:9 Page 6 of 11
reviewing the literature about reasons to make an exception
to the general rule of informed consent for research with
an intervention: distress or confusion, practical problems,
and data validity and quality. Further, the meta-category of
ethical reasons or objections was found to overarch these
categories. In the reviewed papers, ethical reasons not
to ask informed consent were almost always mentioned
alongside arguments in one of the main three categories.
For example, in many cases it was argued that it is uneth-
ical to conduct research that will yield poor quality data
and invalid study results.
Practical arguments against the informed consent re-
quirement come primarily from the field of emergency
research, implementation science and proponents of
the Zelen design. Key issues in these categories are that
research should be of societal importance, should ex-
pose participants to no or (relatively) low risks, that
IRB approval should be obtained, and that data should
be appropriately protected. These issues are more ex-
plicitly discussed in the category of practical problems
rather than the categories of data quality and participant
distress. This might be because emergency research has
been discussed more thoroughly than other types of
research. We would argue, however, that such conditions,
describing when research with a waiver might be conducted
responsibly, could also be valuable for researchers in other
fields of research in which a waiver might be used.
Data validity and quality is mentioned as the main ar-
gument to waive consent for some types of research,
such as research with self-reported outcomes or research
in which the intervention consists of giving information
in such a way that informing people about the study
arms would interfere with the outcome. Bias, due to par-
ticipants’ preference for one of the study arms or due to
the higher chance of part of the potential participants
(e.g., minority group members) to decline participation,
is however the most common argument.
Our review also indicates that not all types of reasons
receive equal attention in the literature. Distress or
confusion does not seem to be an important category
in and of itself. No important research types mentioned
only the distress caused by a consent procedure as a rea-
son not to ask informed consent. The distress argument
was always given in addition to arguments in one or more
of the other categories. Also the argument of practical
problems was often given in addition to other arguments,
with the exception of very large studies. Importantly, this
does not mean that practical problems are not important:
for emergency research many authors have raised con-
cerns about practical problems with asking informed con-
sent. Although it is not the only argument, it is the most
important argument given by many authors. Arguments
such as inferior data quality, the potential distress caused
to patients, and serving societal goals, often provide an
additional basis for requesting a waiver.
The most often discussed research designs and disciplines
can be found in two or three of the categories (Fig. 2). The
distress or confusion that a consent procedure might cause
to (potential) participants and the practical problems ac-
companying it most often are used to justify the consent
waiver for cluster-randomized trials or (other) studies in
implementation science. This is also the case for emergency








































































Fig. 2 Visualization of the relationship between the different study types and reasons to waive informed consent
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research and studies for which a Zelen design has been
suggested, with the addition of a decrease in data quality.
Professionals thus saw different types of reasons why it is
undesirable to always ask informed consent in these
research situations. It seems clear that the likelihood
of the (perceived) need for an informed consent waiver
in a specific type of research increases when the difficulties
related to informed consent span different categories. Al-
though it should be no surprise that more reasons take up
more space in the literature, it seems equally likely that
when there are several types of difficulties with asking in-
formed consent, more researchers find a waiver accept-
able, for instance because it becomes more difficult to find
other solutions.
Ultimately, it is the researcher’s responsibility to provide
sufficient argumentation for waiving informed consent,
and that of the IRB to weigh the arguments carefully be-
fore granting such a waiver for any given project. This
often involves subjective judgment since, to the best of
our knowledge, no criteria have been put forward that
indicate the extent to which any argument (e.g., patient
distress, study bias, etc.) is sufficiently strong to warrant a
consent waiver.
Usage of consent waivers in practice
Statements found in the literature that researchers only
consider a consent waiver after careful consideration of
different factors corresponds with our own experience.
As noted in the introduction, we conducted a study that
inspired us to review reasons to waive informed consent.
In this study, we compared three different consent proce-
dures for the use of residual tissue for scientific research
in a randomized controlled trial [8]. During this study, it
appeared to be very confusing for patients to be asked in-
formed consent for an intervention study with three arms
comparing different consent procedures. Therefore, when
we were planning a larger study to replicate our initial
findings, we requested and were granted a consent waiver.
This was based on several arguments, including the fact
that patients could be confused by being asked for in-
formed consent within the context of an informed consent
intervention, that it was important for the study proce-
dures to mirror actual medical practice, and that the
intervention was non-invasive.
Not all of the reviewed research types and designs find
equal support in the medical research community. The
Zelen design is controversial, most notably because it is
considered unethical to observe people who are unaware
of being randomized to a study, and because it requires
a larger sample size than regular randomization due to
patients not willing to receive the treatment of the inter-
vention arm (e.g. [42, 45, 122]). This research design is
therefore seldom used in practice [28].
However, arguments in favor of waiving consent in some
specific situations in emergency research were sufficiently
convincing to be incorporated in official rules and regula-
tions. For the Declaration of Helsinki, the addition of this
waiver in the fifth edition in 2000 represented an important
change in the informed consent requirements [54].
Future research
Future research may benefit from a focus on two topics.
First, the current literature on consent waivers mainly
focuses on Western countries. More research is needed
on exceptions to the general rule of informed consent in
non-Western cultures. Secondly, not much is known of
the patients’ views on waiving consent. Although some
research has been conducted, these studies all concern
using a waiver for emergency research (e.g. [123, 124]).
In 2008, Lecouturier et al. [125] concluded in their re-
view on participants’ views about research without in-
formed consent specifically in the emergency setting
that insufficient information was available to draw any
firm conclusions.
Conclusions
What does this all mean for researchers preparing an
intervention study with a consent waiver? First, it is im-
portant to keep in mind that situations justifying consent
waiver are always an exception to the rule. Informed
consent should always remain the standard in research
with an intervention. Moreover, researchers always
need to comply with the rules and guidelines applicable
in their country, institute and research field. When these
criteria are fulfilled, Fig. 2 may be used to oversee the
types of reasons legitimized by others in different types of
studies. These reasons can be used by research groups to
form their own opinions on whether, and under which
conditions they find waiving informed consent in their
own study appropriate. Importantly, researchers should
think through whether the arguments they believe to be
legitimate are valid for all parts of an informed consent
procedure. For instance, in some cases, waiving consent
for an intervention could be appropriate, whereas consent,
deferred consent, or deferred proxy consent, may be asked
for the use of a patient’s data. This distinction is not com-
monly made in the literature we reviewed.
We wish to stress that the reasons to waive consent
mentioned above are not the only reasons that could
justify a consent waiver. Other situations not discussed
in the literature may arise, and the reasons to waive
consent mentioned in this paper may serve as examples
that are acceptable according to at least part of the re-
search community. Further, the above review is not an
ethical analysis. Moreover, different cultural settings or
personal believes may differ. Therefore, some readers
may disagree with waiving informed consent in some of
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the studies mentioned in this paper. Importantly, re-
searchers should also take the conditions under which
such an exception is justified into consideration, such
as additional privacy protection measures. Although ul-
timately it is the IRB that will approve or disapprove re-
quests to waive standard informed consent procedures,
it behooves researchers to discuss their argumentation
with relevant stakeholders, including other scientists,
ethicists, physicians, and patient representatives before
submitting a formal request to an IRB. Ultimately, it is
the creation of consensus among relevant stakeholders
that will legitimate any decision to deviate from the
standard rules and regulations governing the conduct
of medical research.
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